Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation

Carcinogenesis

Volumn 31, Issue 4, 2010, Pages 695-702

  Yang, Xiaohe ^a   Yang, Shihe ^a   McKimmey, Christine ^a   Liu, Bolin ^b   Edgerton, Susan M ^b   Bales, Wesley ^c   Archer, Linda T ^c   Thor, Ann D ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TAMOXIFEN; CDKN1B PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DIET; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL CYCLE S PHASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENISTEIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; S PHASE; TAMOXIFEN;

EID: 77249116901     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq007     Document Type: Article

References (46)

1. Messina, M.J. et al. (1994) Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 21, 113-131.
2. Lamartiniere, C.A. (2000) Protection against breast cancer with genistein: a component of soy. Am. J. Clin. Nutr., 71, 1705S-1707S; discussion 1708S-1709S.
3. Cotroneo, M.S. et al. (2002) Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis, 23, 1467-1474.
4. Yang, X. et al. (2003) Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res., 63, 2425-2433.
5. Allred, C.D. et al. (2001) Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res., 61, 5045-5050.
6. Ju, Y.H. et al. (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res., 62, 2474-2477.
7. Liu, B. et al. (2005) Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res., 65, 879-886.
8. Margeat, E. et al. (2003) Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J. Mol. Biol., 326, 77-92.
9. Miodini, P. et al. (1999) The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. Br. J. Cancer, 80, 1150-1155.
10. Li, Y. et al. (1999) Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene, 18, 3166-3172.
11. Akiyama, T. et al. (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262, 5592-5595.
12. Lu, C. et al. (2003) Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J. Natl Cancer Inst., 95, 1825-1833.
13. Wei, H. et al. (1995) Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc. Soc. Exp. Biol. Med., 208, 124-130.
14. Markovits, J. et al. (1989) Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res., 49, 5111-5117.
15. Constantinou, A.I. et al. (1998) Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur. J. Cancer, 34, 1927-1934.
16. Clark, G.M. et al. (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol., 2, 1102-1109.
17. McDonnell, D.P. (2005) The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin. Cancer Res., 11, 871s-877s.
18. Sorlie, T. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA, 98, 10869-10874.
19. Sorlie, T. et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA, 100, 8418-8423.
20. Hynes, N.E. et al. (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198, 165-184.
21. Liu, E. et al. (1992) The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene, 7, 1027-1032.
22. Thor, A.D. et al. (2000) Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol., 18, 3230-3239.
23. Benz, C.C. et al. (1993) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24, 85-95.
24. Alhasan, S.A. et al. (1999) Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr. Cancer, 34, 12-19.
25. Shou, J. et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst., 96, 926-935.
26. Gutierrez, M.C. et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol., 23, 2469-2476.
27. Wang, C. et al. (1997) Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr. Cancer, 28, 236-247.
28. Li, Y. et al. (1999) Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int. J. Oncol., 15, 525-533.
29. Yu, D. et al. (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 13, 1359-1365.
30. Yang, X.H. et al. (2001) Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin-and etoposide-induced apoptosis. Cancer Res., 61, 348-354.
31. Rae, J.M. et al. (2007) MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat., 104, 13-19.
32. Chambers, A.F. (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res., 69, 5292-5293.
33. Akiyama, T. et al. (1991) Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Meth. Enzymol., 201, 362-370.
34. Keshamouni, V.G. et al. (2002) Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J. Biol. Chem., 277, 22558-22565.
35. Surmacz, E. et al. (2004) Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J. Exp. Clin. Cancer Res., 23, 385-394.
36. Kato, S. et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science, 270, 1491-1494.
37. Campbell, R.A. et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem., 276, 9817-9824.
38. Schiff, R. et al. (2005) Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother. Pharmacol., 56 (suppl. 1), 10-20.
39. Blain, S.W. et al. (2003) p27 as a target for cancer therapeutics. Cancer Cell, 3, 111-115.
40. Shin, I. et al. (2002) PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med., 8, 1145-1152.
41. Viglietto, G. et al. (2002) Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med., 8, 1136-1144.
42. Lenferink, A.E. et al. (2001) ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res., 61, 6583-6591.
43. Peterson, G. et al. (1993) Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate, 22, 335-345.
44. Ju, Y.H. et al. (2001) Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J. Nutr., 131, 2957-2962.
45. Messina, M.J. et al. (2001) Soy for breast cancer survivors: a critical review of the literature. J. Nutr., 131, 3095S-3108S.
46. Shyamala, G. et al. (2006) Effect of c-neu/ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res., 66, 10391-10398.